Free Trial

Avalo Therapeutics (AVTX) Stock Price, News & Analysis

-0.18 (-1.62%)
(As of 05/21/2024 ET)
Today's Range
50-Day Range
52-Week Range
15,365 shs
Average Volume
454,169 shs
Market Capitalization
$11.25 million
P/E Ratio
Dividend Yield
Price Target
AVTX stock logo

About Avalo Therapeutics Stock (NASDAQ:AVTX)

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

AVTX Stock Price History

AVTX Stock News Headlines

Why Is Avalo Therapeutics (AVTX) Stock Up 326% Today?
Avalo (AVTX) to Report Q4 Earnings: What's in the Cards?
Avalo Therapeutics Announces 1-for-240 Reverse Stock Split
Avalo Therapeutics Inc AVTX
Avalo Completes Divestiture of AVTX-800 Series
See More Headlines
Receive AVTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avalo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$1.92 million
Book Value
$9.11 per share


Free Float
Market Cap
$11.19 million
Not Optionable
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Garry A. Neil M.D. (Age 70)
    Chairman of the Board, President & CEO
    Comp: $475k
  • Mr. Christopher Ryan SullivanMr. Christopher Ryan Sullivan (Age 40)
    CFO & Head of Investor relations
    Comp: $350k
  • Dr. Solomon H. Snyder M.D. (Age 85)
    Founder and Chairman of Scientific Advisory Board
  • Dr. Barbara S. Slusher Ph.D. (Age 59)
    Founder and Member of Scientific Advisory Board
  • Dr. Lisa Hegg Ph.D.
    Senior Vice President of Program Management, Corporate Infrastructure & Clinical Operations
  • Ms. Colleen Matkowski
    Senior Vice President of Global Regulatory Affairs & Quality Assurance
  • Dr. Dino C. Miano Ph.D.
    Senior Vice President of CMC & Technical Operations

AVTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Avalo Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avalo Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AVTX shares.
View AVTX analyst ratings
or view top-rated stocks.

How have AVTX shares performed in 2024?

Avalo Therapeutics' stock was trading at $9.10 at the beginning of 2024. Since then, AVTX shares have increased by 19.3% and is now trading at $10.86.
View the best growth stocks for 2024 here

When is Avalo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our AVTX earnings forecast

How were Avalo Therapeutics' earnings last quarter?

Avalo Therapeutics, Inc. (NASDAQ:AVTX) released its quarterly earnings results on Wednesday, March, 2nd. The company reported ($460.80) earnings per share for the quarter, missing analysts' consensus estimates of ($432.00) by $28.80. Avalo Therapeutics had a negative net margin of 1,639.50% and a negative trailing twelve-month return on equity of 1,439.87%.

When did Avalo Therapeutics' stock split?

Shares of Avalo Therapeutics reverse split on Friday, December 29th 2023. The 1-240 reverse split was announced on Friday, December 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

Who are Avalo Therapeutics' major shareholders?

Avalo Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Ikarian Capital LLC (4.51%), Affinity Asset Advisors LLC (0.97%), Natixis (0.24%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Armistice Capital, Llc, Caissa Capital Management Ltd, Christopher Ryan Sullivan, Garry Arthur Neil, H Jeffrey Wilkins and Schond L Greenway.
View institutional ownership trends

How do I buy shares of Avalo Therapeutics?

Shares of AVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AVTX) was last updated on 5/21/2024 by Staff

From Our Partners